Up to $A3.73M if gross revenue from LeMaitre CardioCel® and VascuCel® product sales exceed $A29.8M in the first 12 months or $A1.8M if gross revenue from product sales exceed $A22.4M in the first 12 months
Up to $A3.73M if gross revenue from LeMaitre CardioCel® and VascuCel® product sales exceed $A44.7M in the second 12 months or $A1.8M if gross revenue from product sales exceed $A33.5M in the second 12 months
Gross revenue - the catch word
Who fix the price of the product? I think it’s LeMaitre.
Wouldn’t they like to provide heavy discount to the product purchasers? In doing so, not only the product get sold like a hot cake (with their marketing channel) and make greater awareness about the product but also do not need to pay AHZ a buck.
I highly doubt AHZ will get any coins from this arrangement.
cheers
Ann: Appendix 4C - quarterly, page-114
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.30 |
Change
-0.650(5.44%) |
Mkt cap ! $238.8M | |||
| Open | High | Low | Value | Volume |
| $11.71 | $11.83 | $11.24 | $346.8K | 29.94K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 90 | $11.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 50 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |